EuroBiotech—More articles of note


> Oculis raised CHF 20 million ($20 million) from backers including Novartis. The Swiss biotech will use the money to advance a phase 2b diabetic macular edema drug. Statement

> Themis raised €10 million ($12 million). The series C gives Themis the means to advance its pipeline of vaccines, including a phase 2 chikungunya virus candidate. Release

> Addex Therapeutics entered into a licensing agreement with Indivior for addiction drug ADX71441. Indivior is paying $5 million (€4 million) upfront and committing to up to $330 million in milestones to buy into the program. Statement


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Galapagos shared an update on its cystic fibrosis programs. Release

Suggested Articles

Sumitovant CEO Myrtle Potter discusses the $3 billion Roivant-Sumitomo deal, her role at Sumitovant and what's up in 2020.

Antibiotics player Summit Therapeutics is gearing up for a new clinical trial of its lead asset, an antibiotic for Clostridium difficile infection.

In this week's EuroBiotech Report, Roche's risdiplam clears another phase 3 SMA trial, Merck KGaA spinout raises cash and Korean VCs back PDC*line.